Intriguingly, in other neurodegenerative diseases (e.g., Alzheimer’s disease (AD), GRN-frontotemporal dementia (GRN-FTD)), and even in older people at high risk for dementia, elevated blood GFAP levels have been reported to have some predictive value, being associated with faster cognitive decline and reduced brain volumes [22]. The gene discussed is GFAP; the disease is neurodegenerative disease.